Navigation auf zora.uzh.ch

Search ZORA

ZORA (Zurich Open Repository and Archive)

DDOS: due to massive botnet requests against our ‘Advanced Search’ we have restricted access to UZH (local and VPN). Thank you for your understanding.

A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations

Hatz, Christoph; Cramer, Jakob P; Vertruyen, André; Schwarz, Tino F; von Sonnenburg, Frank; Borkowski, Astrid; Lattanzi, Maria; Hilbert, Anne Katrin; Cioppa, Giovanni Della; Leroux-Roels, Geert (2012). A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations. Vaccine, 30(32):4820-4827.

Abstract

BACKGROUND: Modern cell-culture production techniques and the use of adjuvants helps to ensure that the global demand for pandemic influenza vaccine can be met. This study aimed to assess the immunogenicty and safety profiles of various cell-culture-derived A/H1N1 pandemic vaccine formulations in healthy adult and elderly subjects.
METHODS: Adult (18-60 years) subjects (n=544) received vaccine either containing 3.75 μg of antigen with half the standard dose of MF59 (Novartis Vaccines and Diagnostics) adjuvant, 7.5 μg antigen with a full dose of MF59, or a non-adjuvanted vaccine containing 15 μg of antigen. Elderly (≥ 61 years) subjects (n=268) received either the 3.75 μg or 7.5 μg adjuvanted formulations. Two priming vaccine doses were administered 3 weeks apart, followed by a single booster dose of seasonal influenza vaccine 1 year later. Immunogenicity was assessed 3 weeks after each vaccination. The safety profile of each formulation was evaluated throughout the study.
RESULTS: A single primary dose of each A/H1N1 vaccine formulation was sufficient to meet all three European (CHMP) licensure criteria for pandemic influenza vaccines in adult subjects. Two licensure criteria were met after one vaccine dose in elderly subjects; two primary doses were required to meet all three criteria in this age group. The highest antibody titres were observed in response to the 7.5 μg vaccine containing a full dose of MF59 adjuvant. All subjects rapidly generated seroprotective antibody titres in response to booster vaccination.
CONCLUSION: This study identified one 3.75 μg vaccine dose containing half the standard dose of MF59 adjuvant as optimal for adults, two doses were optimal for elderly subjects. The antigen-sparing properties of MF59, and rapid, modern, cell-culture production techniques represent significant steps towards meeting the global demand for influenza vaccine.

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > Epidemiology, Biostatistics and Prevention Institute (EBPI)
Dewey Decimal Classification:610 Medicine & health
Scopus Subject Areas:Life Sciences > Molecular Medicine
Life Sciences > General Immunology and Microbiology
Health Sciences > General Veterinary
Health Sciences > Public Health, Environmental and Occupational Health
Health Sciences > Infectious Diseases
Language:English
Date:2012
Deposited On:18 Jan 2013 07:18
Last Modified:08 Jun 2025 01:36
Publisher:Elsevier
ISSN:0264-410X
OA Status:Closed
Publisher DOI:https://doi.org/10.1016/j.vaccine.2012.05.013
PubMed ID:22626675

Metadata Export

Statistics

Citations

Dimensions.ai Metrics
20 citations in Web of Science®
21 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

0 downloads since deposited on 18 Jan 2013
0 downloads since 12 months

Authors, Affiliations, Collaborations

Similar Publications